NeoPharm Co Ltd
KOSDAQ:092730
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
|
US |
NeoPharm Co Ltd
Operating Income
NeoPharm Co Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
NeoPharm Co Ltd
KOSDAQ:092730
|
Operating Income
₩28.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
6%
|
CAGR 10-Years
16%
|
|
|
AmorePacific Corp
KRX:090430
|
Operating Income
₩335.8B
|
CAGR 3-Years
16%
|
CAGR 5-Years
19%
|
CAGR 10-Years
-8%
|
|
|
Amorepacific Group
KRX:002790
|
Operating Income
₩368B
|
CAGR 3-Years
11%
|
CAGR 5-Years
20%
|
CAGR 10-Years
-9%
|
|
|
Cosmax Inc
KRX:192820
|
Operating Income
₩195.8B
|
CAGR 3-Years
54%
|
CAGR 5-Years
24%
|
CAGR 10-Years
18%
|
|
|
LG H&H Co Ltd
KRX:051900
|
Operating Income
₩170.7B
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-13%
|
|
|
Kolmar Korea Co Ltd
KRX:161890
|
Operating Income
₩239.6B
|
CAGR 3-Years
48%
|
CAGR 5-Years
15%
|
CAGR 10-Years
15%
|
|
NeoPharm Co Ltd
Glance View
NeoPharm Co., Ltd. engages in the development, manufacture, and sale of cosmetics, medical, and health products. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2007-01-30. The firm produces its products under brand names of ATOPALM, including daily care, intensive care, special care and baby care products; Derma:B, including foam cleansers, oil cleansers, toners, emulsions, creams, facial masks, blemish base (BB) creams, sun protectors, white watering serums, anti-aging eye creams and others; ZEROID, including creams and lotions for recovering damaged skin barriers and hypollalergenic foaming cleansers for atopy and sensitive skins, and others. The company also engages in the original equipment manufacturing (OEM) of skin drugs.
See Also
What is NeoPharm Co Ltd's Operating Income?
Operating Income
28.8B
KRW
Based on the financial report for Dec 31, 2025, NeoPharm Co Ltd's Operating Income amounts to 28.8B KRW.
What is NeoPharm Co Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
16%
Over the last year, the Operating Income growth was 17%. The average annual Operating Income growth rates for NeoPharm Co Ltd have been 10% over the past three years , 6% over the past five years , and 16% over the past ten years .
